GSK PLC
GSK: XLON (GBR)
| Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
|---|---|---|---|
| LOCK|$YL | LOCK|Q!b | LOCK|!>CG!T# |
GSK Earnings: Growth Franchises Offset Weak Vaccines
GSK reported 5% year-over-year sales growth at constant currency and a core operating margin of 34.6%. Management reaffirmed its previous full-year guidance of 3%-5% constant-currency sales growth and 7%-9% core operating profit growth, with both expected in the upper half of their ranges.
